Short Interest Watching: Vanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Has Decline in Shorts

November 21, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Watching: Vanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Has Decline in Shorts

The stock of Vanda Pharmaceuticals Incorporated (NASDAQ:VNDA) registered a decrease of 11.57% in short interest. VNDA’s total short interest was 2.71M shares in November as published by FINRA. Its down 11.57% from 3.07M shares, reported previously. With 835,900 shares average volume, it will take short sellers 3 days to cover their VNDA’s short positions. The short interest to Vanda Pharmaceuticals Incorporated’s float is 10.39%. The stock decreased 0.29% or $0.05 on November 18, hitting $17. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 89.73% since April 19, 2016 and is uptrending. It has outperformed by 85.87% the S&P500.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $744.90 million. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Insitutional Activity: The institutional sentiment increased to 2.39 in 2016 Q2. Its up 1.37, from 1.02 in 2016Q1. The ratio is positive, as 19 funds sold all Vanda Pharmaceuticals Inc. shares owned while 33 reduced positions. 19 funds bought stakes while 34 increased positions. They now own 36.20 million shares or 6.54% less from 38.73 million shares in 2016Q1.
Principal Fincl Grp holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 203,600 shares. D E Shaw And Incorporated owns 219,757 shares or 0% of their US portfolio. Paloma Prtnrs owns 17,150 shares or 0% of their US portfolio. New York State Common Retirement Fund accumulated 40,300 shares or 0% of the stock. Pacad Investment Limited accumulated 0.01% or 6,200 shares. Allianz Asset Mgmt Ag, a Germany-based fund reported 48,140 shares. Gemmer Asset Mgmt Limited Liability, a California-based fund reported 594 shares. Qs Invsts Ltd Liability Corporation last reported 470,965 shares in the company. Amer International has 21,095 shares for 0% of their US portfolio. State Board Of Administration Of Florida Retirement has 89,624 shares for 0% of their US portfolio. Cornerstone Mngmt Ltd Liability Co has 0.02% invested in the company for 187,100 shares. Bank Of America De last reported 36,406 shares in the company. Tiaa Cref Investment Management Ltd holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 298,773 shares. Alliancebernstein Ltd Partnership reported 126,078 shares or 0% of all its holdings. The Georgia-based Ridgeworth Cap Mgmt Ltd Liability Corporation has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Insider Transactions: Since September 15, 2016, the stock had 0 buys, and 2 sales for $27.14 million net activity. Flynn James E had sold 547,886 shares worth $8.58M on Thursday, September 15.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Out of 5 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $24 is the highest target while $15 is the lowest. The $19.40 average target is 14.12% above today’s ($17) stock price. Vanda Pharmaceuticals has been the topic of 7 analyst reports since September 2, 2015 according to StockzIntelligence Inc. As per Wednesday, November 9, the company rating was initiated by Aegis Capital. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, October 21 by Brean Capital. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, March 9 with “Market Outperform” rating. The rating was reinitiated by Jefferies with “Buy” on Thursday, October 6. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Friday, August 26 with “Market Outperform” rating. On Wednesday, September 2 the stock rating was maintained by Piper Jaffray with “Buy”.

VNDA Company Profile

Vanda Pharmaceuticals Inc., incorporated on November 13, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Prnewswire.com which released: “Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro” on October 24, 2016, also Prnewswire.com with their article: “Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results” published on November 02, 2016, Prnewswire.com published: “Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on …” on October 12, 2016. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on July 27, 2016 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial …” with publication date: December 17, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>